Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL10886792 | 0.92 | ADRA2B (0.55) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL27230567 | 0.85 | ADRA2B (0.60) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL29268868 | 0.83 | ADRA2B (0.58) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL530326 | 0.82 | ADRA2B (0.67) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL5724555 | 0.80 | ADRA2B (0.55) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL1593286 | 0.80 | TSHR (0.50) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL79748 | 0.80 | TSHR (0.50) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL8699772 | 0.79 | ADRA2B (0.53) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL19203450 | 0.79 | ADRA2B (0.69) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 | |
| SCHEMBL9475521 | 0.79 | ADRA2B (0.53) | ADRA2BADRA2CSLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600748-B2 | Affinity chromatography of immunoglobulins by using pre-capture flocculation | RICHTER GEDEON NYRT. (HU) | 2026-04-14 | — | — | US | claimed |
| US-12540160-B2 | Methods for the purification of refolded Fc-peptide fusion protein | RICHTER GEDEON NYRT. (HU) | 2026-02-03 | — | — | US | claimed |
| EP-4263568-B1 | METHODS FOR THE PURIFICATION OF REFOLDED FC-PEPTIDE FUSION PROTEIN | RICHTER GEDEON NYRT (HU) | 2025-06-18 | — | — | EP | claimed |
| US-12331193-B2 | Hydrophobically modified alkylene oxide polymer mixture | ROHM AND HAAS COMPANY (US) | 2025-06-17 | — | — | US | claimed |
| EP-4058498-B1 | HYDROPHOBICALLY MODIFIED ALKYLENE OXIDE POLYMER MIXTURE | ROHM & HAAS (US) | 2025-03-12 | — | — | EP | claimed |
| CN-115397552-B | Separation matrix and separation method | 思拓凡生物工艺研发有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118909074-A | Efficient purification method of recombinant human platelet-derived growth factor BB | 华芢生物科技(青岛)股份有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-115197311-B | Purification method of recombinant human interleukin 12 protein | 康立泰生物医药(青岛)有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240343758-A1 | PROCESS FOR PURIFICATION OF PROTEIN | ACQUIOM AGENCY SERVICES, AS COLLATERAL AGENT | 2024-10-17 | — | — | US | claimed |
| CN-113710685-B | Affinity chromatography for immunoglobulins by using flocculation prior to capture | 吉瑞工厂 | 2024-10-01 | — | — | CN | claimed |
| EP-2190486-A2 | A PROCESS FOR ISOLATION AND PURIFICATION OF A TARGET PROTEIN FREE OF PRION PROTEIN (PRPSC) | Octapharma AG (CH) | 2010-06-02 | — | — | EP | claimed |
| WO-2010030222-A1 | ENHANCED PROTEIN AGGREGATE REMOVAL WITH MULTIMODAL ANION EXCHANGERS IN THE PRESENCE OF PROTEIN-EXCLUDED ZWITTERIONS | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2010-03-18 | — | — | WO | claimed |
| WO-2009156430-A1 | A PROCESS OF PURIFYING COAGULATION FACTOR VIII | OCTAPHARMA AG (CH) | 2009-12-30 | — | — | WO | claimed |
| WO-2009024620-A2 | A PROCESS FOR ISOLATION AND PURIFICATION OF A TARGET PROTEIN FREE OF PRION PROTEIN (PRPSC) | OCTAPHARMA AG (CH) | 2009-02-26 | — | — | WO | claimed |
| EP-2027875-A1 | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) | Octapharma AG (CH) | 2009-02-25 | — | — | EP | claimed |
| CN-101060931-A | Antibodies by chromatography | GE HEALTHCARE BIO SCIENCES AB (SE) | 2007-10-24 | — | — | CN | claimed |
| US-20070244307-A1 | N-benzyl-N-methyl ethanol amine; a mobile phase comprising sample is contacted with a multi-modal separation matrix to adsorb undesired compounds while the antibodies remain free in the liquid; requires less time and process steps than the prior art methods | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-10-18 | — | — | US | claimed |
| WO-2007006585-A2 | SYNTHESIS OF A POROUS AND/OR STRATIFIED STRUCTURE MANGANESE OXIDE | ELSPER RUEDIGER (DE) | 2007-01-18 | — | — | WO | claimed |
| US-5463094-A | Solvent free quaternization of tertiary amines with dimethylsulfate | HOECHST CELANESE CORPORATION (US) | 1995-10-31 | — | — | US | claimed |
| EP-0186326-B1 | ACID ANHYDRIDE MIXTURES IN PASTE FORM USEFUL FOR CURING EPOXY RESINS AND A DUAL CATALYST SYSTEM THEREFOR | FORD MOTOR COMPANY LIMITED (GB) | 1989-07-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600748-B2 | Affinity chromatography of immunoglobulins by using pre-capture flocculation | FCGR1A, FCGR2A, FCGR3B | ADRA2B 3522/4885ADRA2C 1989/4885SLC6A2 3871/4885 |
| US-12540160-B2 | Methods for the purification of refolded Fc-peptide fusion protein | PDIA5, MRPL21, RPS27A | ADRA2B 3090/4885ADRA2C 3457/4885SLC6A2 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.